Conference Schedule: Molecular Partners will showcase its latest developments and 2025 outlook at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, with CEO Patrick Amstutz presenting on January 15 from 10:30 to 11:10 AM PT, likely drawing investor interest.
Technological Innovation: The company focuses on developing DARPin therapeutics aimed at addressing medical challenges that other drug modalities cannot effectively tackle, highlighting its innovative potential in the biotech sector.
Clinical Progress: Molecular Partners has made advancements in various clinical and preclinical programs, particularly in oncology, indicating a promising clinical application outlook for its product candidates, which could enhance future market acceptance.
Financial Outlook: The company anticipates reporting its business and financial outlook for 2025, and while facing market uncertainties, its cash flow and expenditure management strategies will be critical factors for sustaining operations.
MOLN
$4.23+Infinity%1D
Analyst Views on MOLN
Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 8.33 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 8.33 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.230
Low
4.00
Averages
8.33
High
12.00
Current: 4.230
Low
4.00
Averages
8.33
High
12.00
JPMorgan
Richard Vosser
Neutral
downgrade
$4
2025-12-08
Reason
JPMorgan
Richard Vosser
Price Target
$4
2025-12-08
downgrade
Neutral
Reason
JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $3.75 from $4 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.
JPMorgan
Neutral
downgrade
2025-12-08
Reason
JPMorgan
Price Target
2025-12-08
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Molecular Partners to CHF 3 from CHF 3.50 and keeps a Neutral rating on the shares.
JPMorgan
Richard Vosser
Neutral
downgrade
$4
2025-09-03
Reason
JPMorgan
Richard Vosser
Price Target
$4
2025-09-03
downgrade
Neutral
Reason
JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $4 from $4.50 and keeps a Neutral rating on the shares.
About MOLN
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
